 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for PRAME |
 Gene summary |
| Basic gene information | Gene symbol | PRAME |
| Gene name | preferentially expressed antigen in melanoma | |
| Synonyms | CT130|MAPE|OIP-4|OIP4 | |
| Cytomap | UCSC genome browser: 22q11.22 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001291715.1, NM_001291716.1,NM_001291717.1,NM_001291719.1,NM_006115.4, NM_206953.2,NM_206954.2,NM_206955.2,NM_206956.2, | |
| Description | Opa-interacting protein OIP4cancer/testis antigen 130melanoma antigen preferentially expressed in tumorsopa-interacting protein 4preferentially expressed antigen of melanoma | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 606021 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000185686 | ||
| HPRD : 05820 | ||
| Vega : OTTHUMG00000151172 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_PRAME | |
| BioGPS: 23532 | ||
| Pathway | NCI Pathway Interaction Database: PRAME | |
| KEGG: PRAME | ||
| REACTOME: PRAME | ||
| Pathway Commons: PRAME | ||
| Context | iHOP: PRAME | |
| ligand binding site mutation search in PubMed: PRAME | ||
| UCL Cancer Institute: PRAME | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | SkinTestis | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | SKCMTGCT | |
| Reference showing the relevant tissue of PRAME | ||
| Description by TissGene annotations | ||
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID | GO:0008284 | positive regulation of cell proliferation | 16179254 | GO:0043066 | negative regulation of apoptotic process | 16179254 | GO:0045596 | negative regulation of cell differentiation | 16179254 | GO:0045892 | negative regulation of transcription, DNA-templated | 16179254 | GO:0048387 | negative regulation of retinoic acid receptor signaling pathway | 16179254 | GO:0008284 | positive regulation of cell proliferation | 16179254 | GO:0043066 | negative regulation of apoptotic process | 16179254 | GO:0045596 | negative regulation of cell differentiation | 16179254 | GO:0045892 | negative regulation of transcription, DNA-templated | 16179254 | GO:0048387 | negative regulation of retinoic acid receptor signaling pathway | 16179254 |
| Top |
| TissGeneExp for PRAME |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| LIHC | -2.176198646 | -4.679242646 | 2.503044 | 2.30E-05 | 8.93E-05 |
| LUAD | -0.665727612 | -4.622524163 | 3.956796552 | 9.28E-11 | 5.52E-10 |
| STAD | -1.317705521 | -4.390583646 | 3.072878125 | 3.46E-06 | 4.76E-05 |
| HNSC | 0.009072749 | -3.844380739 | 3.853453488 | 3.92E-07 | 3.35E-06 |
| BRCA | -0.602571804 | -3.199474436 | 2.596902632 | 4.89E-09 | 1.66E-08 |
| LUSC | 3.282609001 | -3.83976943 | 7.122378431 | 9.99E-21 | 1.29E-19 |
| KICH | -4.355992646 | -1.595108646 | -2.760884 | 3.01E-07 | 1.25E-06 |
| BLCA | -0.981650751 | -3.877108646 | 2.895457895 | 0.0104 | 0.046632258 |
| ESCA | 0.64335499 | -4.252890464 | 4.896245455 | 0.00145 | 0.018640462 |
| KIRC | 0.697317743 | -0.891040591 | 1.588358333 | 0.000223 | 0.000455139 |
| PRAD | -2.752681723 | -4.549450954 | 1.796769231 | 8.12E-05 | 0.000349269 |
| KIRP | 1.355406979 | -0.940093021 | 2.2955 | 7.66E-05 | 0.000270027 |
| Top |
| TissGene-miRNA for PRAME |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| Top |
| TissGeneMut for PRAME |
| TissGeneSNV for PRAME |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.W7R | BRCA | 2 |
| p.L411S | SKCM | 1 |
| p.S274F | SKCM | 1 |
| p.R113C | SKCM | 1 |
| p.A217P | BLCA | 1 |
| p.E169K | LUAD | 1 |
| p.S145* | BRCA | 1 |
| p.L266F | LUAD | 1 |
| p.S253F | SKCM | 1 |
| p.D497E | LUAD | 1 |
| p.S419F | SKCM | 1 |
| p.P500L | SKCM | 1 |
| p.D102V | LUAD | 1 |
| p.F308S | SKCM | 1 |
| p.W7R | COAD | 1 |
| p.P504S | SKCM | 1 |
| p.R159Q | BRCA | 1 |
| p.R125Q | HNSC | 1 |
| p.S447N | BRCA | 1 |
| p.P54S | PCPG | 1 |
| p.V480A | KIRC | 1 |
| p.Q291L | SARC | 1 |
| p.G311C | LUAD | 1 |
| p.G453V | LUSC | 1 |
| p.M259T | LIHC | 1 |
| p.H91R | GBM | 1 |
| p.R201* | STAD | 1 |
| p.P444S | SKCM | 1 |
| p.W7R | HNSC | 1 |
| p.N139S | LIHC | 1 |
| p.G257S | LUSC | 1 |
| p.R159* | UCEC | 1 |
| p.I196M | PAAD | 1 |
| p.L213M | ESCA | 1 |
| p.I196T | BLCA | 1 |
| p.D189N | UCEC | 1 |
| p.R201X | STAD | 1 |
| p.F182S | STAD | 1 |
| p.R207H | GBM | 1 |
| p.H65N | LUAD | 1 |
| p.T410N | LUAD | 1 |
| p.P174S | SKCM | 1 |
| p.L426I | ESCA | 1 |
| p.H271R | READ | 1 |
| p.S234A | COAD | 1 |
| p.S335L | GBM | 1 |
| p.L47M | DLBC | 1 |
| p.L313R | HNSC | 1 |
| p.P23Q | LUAD | 1 |
| p.A286T | READ | 1 |
| p.G453D | SKCM | 1 |
| p.C503R | UCEC | 1 |
| p.R312L | THYM | 1 |
| p.S425T | LUSC | 1 |
| p.R125W | STAD | 1 |
| p.S22N | STAD | 1 |
| p.L502M | COAD | 1 |
| p.L423F | BRCA | 1 |
| p.L47M | COAD | 1 |
| p.G103R | SKCM | 1 |
| p.L119R | HNSC | 1 |
| p.E169* | LUAD | 1 |
| p.E374G | LUAD | 1 |
| p.R466M | UCEC | 1 |
| p.Q344* | BLCA | 1 |
| p.K200* | LUAD | 1 |
| p.E282Q | LUAD | 1 |
| p.Q315* | SKCM | 1 |
| p.W244* | SKCM | 1 |
| p.R263C | STAD | 1 |
| p.E51K | SKCM | 1 |
| p.G31E | SKCM | 1 |
| p.Q287P | HNSC | 1 |
| p.L482R | LIHC | 1 |
| p.V439M | LUAD | 1 |
| p.E279K | SKCM | 1 |
| p.R3* | LUAD | 1 |
| p.L426V | LUAD | 1 |
| p.Q153* | BLCA | 1 |
| p.P486S | SKCM | 1 |
| p.S335L | SKCM | 1 |
| p.L45M | UCEC | 1 |
| p.S478C | LUSC | 1 |
| p.R5C | UCEC | 1 |
| Top |
| TissGeneCNV for PRAME |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for PRAME |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| TCGAfusionPortal | PRADA | SKCM | TCGA-BF-A5EQ-01A | PRAME-ACO2 | Out-of-frame | Chr22:22899232 | Chr22:41903795 |
| TCGAfusionPortal | PRADA | SKCM | TCGA-EB-A3Y6-01A | PRAME-HDLBP | NA | Chr22:22890128 | Chr2:242202277 |
| Top |
| TissGeneNet for PRAME |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| PRAME, CUL2, RFC4, HNRNPC, TCEB1, RPL10, HNRNPF, BAG2, TCEB2, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, STK19, RPS13, UBE2F (tumor) | PRAME, CUL2, RFC4, HNRNPC, TCEB1, HNRNPF, BAG2, PSMC4, TCEB2, LAGE3, RBX1, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, TPRKB, STK19, RPS13, UBE2F (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| PRAME, CUL2, RFC4, HNRNPC, TCEB1, HNRNPF, BAG2, TCEB2, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, TPRKB, STK19, RPS13, UBE2F (tumor) | PRAME, CUL2, RFC4, HNRNPC, TCEB1, RPL10, BAG2, PSMC4, TCEB2, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, HNRNPH1, KDM1A, TPRKB, STK19, RPS13, UBE2F (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| PRAME, CUL2, RFC4, HNRNPC, TCEB1, RPL10, BAG2, PSMC4, TCEB2, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, TPRKB, RPS13, UBE2F (tumor) | PRAME, CUL2, RFC4, HNRNPC, TCEB1, HNRNPF, BAG2, PSMC4, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, TPRKB, STK19, RPS13, UBE2F (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| PRAME, RFC4, HNRNPC, TCEB1, RPL10, HNRNPF, BAG2, PSMC4, TCEB2, LAGE3, RBX1, NEDD8, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, TPRKB, STK19, RPS13, UBE2F (tumor) | PRAME, CUL2, RFC4, TCEB1, RPL10, HNRNPF, BAG2, PSMC4, TCEB2, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, TPRKB, STK19, UBE2F (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| PRAME, CUL2, RFC4, HNRNPC, TCEB1, BAG2, PSMC4, TCEB2, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, TPRKB, STK19, RPS13, UBE2F (tumor) | PRAME, CUL2, RFC4, HNRNPC, TCEB1, RPL10, HNRNPF, BAG2, PSMC4, TCEB2, LAGE3, RBX1, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, TPRKB, STK19, RPS13, UBE2F (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| PRAME, CUL2, HNRNPC, TCEB1, RPL10, HNRNPF, BAG2, PSMC4, TCEB2, LAGE3, RBX1, NEDD8, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, TPRKB, STK19, RPS13, UBE2F (tumor) | PRAME, CUL2, RFC4, TCEB1, RPL10, HNRNPF, BAG2, PSMC4, TCEB2, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, TPRKB, STK19, RPS13, UBE2F (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| PRAME, CUL2, RFC4, HNRNPC, TCEB1, RPL10, HNRNPF, BAG2, PSMC4, TCEB2, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, RPS13, UBE2F (tumor) | PRAME, CUL2, RFC4, HNRNPC, TCEB1, RPL10, HNRNPF, PSMC4, TCEB2, LAGE3, RBX1, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, TPRKB, STK19, RPS13, UBE2F (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| PRAME, CUL2, RFC4, HNRNPC, TCEB1, RPL10, HNRNPF, BAG2, PSMC4, TCEB2, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, RPL22, TPRKB, STK19, RPS13, UBE2F (tumor) | PRAME, CUL2, RFC4, HNRNPC, TCEB1, RPL10, HNRNPF, BAG2, PSMC4, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, TPRKB, RPS13, UBE2F (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| PRAME, CUL2, RFC4, HNRNPC, TCEB1, RPL10, BAG2, PSMC4, TCEB2, LAGE3, RBX1, NEDD8, OSGEP, UBL4A, RPL22, HNRNPH1, KDM1A, TPRKB, STK19, RPS13, UBE2F (tumor) | PRAME, CUL2, RFC4, HNRNPC, RPL10, BAG2, PSMC4, TCEB2, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, TPRKB, STK19, RPS13, UBE2F (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| PRAME, CUL2, RFC4, HNRNPC, TCEB1, RPL10, HNRNPF, BAG2, PSMC4, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, TPRKB, RPS13, UBE2F (tumor) | PRAME, CUL2, RFC4, HNRNPC, TCEB1, RPL10, HNRNPF, PSMC4, TCEB2, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, STK19, RPS13, UBE2F (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| PRAME, CUL2, RFC4, HNRNPC, RPL10, HNRNPF, BAG2, PSMC4, TCEB2, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, RPL22, HNRNPH1, KDM1A, STK19, RPS13, UBE2F (tumor) | PRAME, CUL2, RFC4, HNRNPC, TCEB1, RPL10, HNRNPF, BAG2, PSMC4, LAGE3, RBX1, NEDD8, OSGEP, UBL4A, RPL22, HNRNPH1, KDM1A, TPRKB, STK19, RPS13, UBE2F (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| PRAME, CUL2, RFC4, HNRNPC, TCEB1, RPL10, HNRNPF, BAG2, PSMC4, TCEB2, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, RPL22, HNRNPH1, KDM1A, TPRKB, STK19, RPS13 (tumor) | PRAME, CUL2, RFC4, HNRNPC, TCEB1, RPL10, HNRNPF, BAG2, PSMC4, TCEB2, LAGE3, RBX1, NEDD8, OSGEP, HNRNPM, UBL4A, RPL22, KDM1A, TPRKB, RPS13, UBE2F (normal) |
 |  |
| Top |
| TissGeneProg for PRAME |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for PRAME |
| TissGeneDrug for PRAME |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for PRAME |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0023467 | Leukemia, Myelocytic, Acute | 17 | BeFree,LHGDN |
| umls:C0023418 | leukemia | 14 | BeFree,CTD_human,LHGDN |
| umls:C0242596 | Neoplasm, Residual | 11 | BeFree,LHGDN |
| umls:C0023473 | Myeloid Leukemia, Chronic | 8 | BeFree,CTD_human |
| umls:C0025202 | melanoma | 7 | BeFree,CTD_human |
| umls:C0153594 | Malignant neoplasm of testis | 6 | BeFree |
| umls:C0085669 | Acute leukemia | 5 | BeFree |
| umls:C0023434 | Chronic Lymphocytic Leukemia | 4 | BeFree |
| umls:C0376545 | Hematologic Neoplasms | 4 | BeFree |
| umls:C0005699 | Blast Phase | 3 | BeFree |
| umls:C0006142 | Malignant neoplasm of breast | 3 | BeFree |
| umls:C0023449 | Acute lymphocytic leukemia | 3 | BeFree |
| umls:C0025149 | Medulloblastoma | 3 | BeFree,CTD_human |
| umls:C0029463 | Osteosarcoma | 3 | BeFree |
| umls:C0280100 | Solid tumour | 3 | BeFree |
| umls:C0585442 | Osteosarcoma of bone | 3 | BeFree |
| umls:C0678222 | Breast Carcinoma | 3 | BeFree |
| umls:C1840451 | MULTICYSTIC RENAL DYSPLASIA, BILATERAL | 3 | BeFree |
| umls:C0001418 | Adenocarcinoma | 2 | BeFree,LHGDN |
| umls:C0023452 | Leukemia, Lymphocytic, Acute, L1 | 2 | BeFree |
| umls:C0024314 | Lymphoproliferative Disorders | 2 | BeFree,LHGDN |
| umls:C0026764 | Multiple Myeloma | 2 | BeFree,CTD_human |
| umls:C0027627 | Neoplasm Metastasis | 2 | BeFree |
| umls:C0079744 | Diffuse Large B-Cell Lymphoma | 2 | BeFree |
| umls:C0220621 | pediatric acute myeloblastic leukemia | 2 | BeFree |
| umls:C1279296 | Chronic leukemia (category) | 2 | BeFree |
| umls:C1961102 | Precursor Cell Lymphoblastic Leukemia Lymphoma | 2 | BeFree,LHGDN |
| umls:C0007131 | Non-Small Cell Lung Carcinoma | 1 | CTD_human |
| umls:C0007134 | Renal Cell Carcinoma | 1 | CTD_human |
| umls:C0018671 | Head and Neck Neoplasms | 1 | CTD_human |
| umls:C0019829 | Hodgkin Disease | 1 | BeFree |
| umls:C0023443 | Hairy Cell Leukemia | 1 | BeFree |
| umls:C0023462 | Acute Megakaryocytic Leukemias | 1 | BeFree |
| umls:C0023487 | Acute Promyelocytic Leukemia | 1 | BeFree,LHGDN |
| umls:C0023492 | Leukemia, T-Cell | 1 | BeFree |
| umls:C0023493 | Adult T-Cell Lymphoma/Leukemia | 1 | BeFree |
| umls:C0023827 | liposarcoma | 1 | BeFree |
| umls:C0024299 | Lymphoma | 1 | BeFree |
| umls:C0025500 | Mesothelioma | 1 | BeFree |
| umls:C0039496 | Temporomandibular Joint Dysfunction Syndrome | 1 | BeFree |
| umls:C0039590 | Testicular Neoplasms | 1 | BeFree |
| umls:C0178874 | Tumor Progression | 1 | BeFree |
| umls:C0206701 | Cystadenocarcinoma, Serous | 1 | BeFree |
| umls:C0220615 | Adult Acute Myeloblastic Leukemia | 1 | BeFree |
| umls:C0334471 | Round cell liposarcoma | 1 | BeFree |
| umls:C0334634 | Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse | 1 | BeFree |
| umls:C0345967 | Malignant mesothelioma | 1 | BeFree |
| umls:C0376544 | Hematopoietic Neoplasms | 1 | BeFree |
| umls:C1168401 | Squamous cell carcinoma of the head and neck | 1 | BeFree |
| umls:C1261473 | Sarcoma | 1 | CTD_human |
| umls:C1292778 | Chronic myeloproliferative disorder | 1 | BeFree |
| umls:C1335475 | Primary Carcinoma | 1 | BeFree |
| umls:C1458155 | Mammary Neoplasms | 1 | LHGDN |
| umls:C1838244 | TIBIAL MUSCULAR DYSTROPHY, TARDIVE | 1 | BeFree |
| umls:C1861922 | CAMPOMELIC DYSPLASIA | 1 | BeFree |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |